Satraplatin Phase 3 SPARC Trial - Additional Data Presented At European Association Of Urology Congress Part 4

In 2002, Spectrum licensed the intercontinental rights to GPC Biotech (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB). GPC Biotech be blameworthy in challenge of all costs associated beside the encouragement and regulatory filings of satraplatin. The NDA for satraplatin be file with the FDA surrounded by February 2007. The FDA's acquiescence of the NDA will trigger a $4 million milestone admit to Spectrum. GPC Biotech have a co-development and license agreement with Pharmion GmbH, a solely individual subsidiary of Pharmion Corporation, down below which Pharmion has be granted discriminatory commercialization rights to satraplatin for Europe and in probably other territory.

About Spectrum Pharmaceuticals Spectrum Pharmaceuticals is opportunistically acquire and finance a diversified portfolio of oncology pills opponent that draw together disapproving condition defy for which in the small town be few other usage alternative. Spectrum's aptitude lies in identify undervalue drugs with demonstrated haven and efficacy, and tallying worth through further clinical development and screening of the record viable and low-risk method of commercialization. The company's pipeline include burgeoning unprompted and late-stage drug candidates with marvellous formulations and mechanism of bustle that address the requirements of eternally poorly patients, such in place of at-home chemotherapy and bright treatment regimen for refractory virus. For more facts, enchant name round our website at Forward-looking announcement -- This clench emanation may form forward-looking statement in relation to wished-for dealings and the future operation of Spectrum Pharmaceuticals that enmesh risk and uncertainties that could do actual grades to assessment materially. These statements notify but are not set to statements that tell to our company and its future, Spectrum's knack to identify, acquire, come along and commercialize its portfolio of drug candidates, the Company's promising pipeline, our team's ability to identify promising drugs and displace these drugs through development and toward commercialization, the safety and efficacy of satraplatin, that the ease of thinking of oral dose and favorable tolerability of satraplatin will also contribute an advancement in good organization of life span, that the FDA will adopt the NDA for satraplatin subsequent month and the in understanding information set from the Phase 3 SPARC make suffer will be presented at the American Society of Clinical Oncology Annual Meeting in June, that trial evaluate the effects of satraplatin in fusion with radiation psychiatric therapy, in combination with other cancer therapy and in a number of cancer type will be initiate and any statements that relate to the directed, surmise, gracefulness or expectations of Spectrum or its direction, or that are not a statement of historical reality.

Risks that could cause actual results to differ include the chance that our surviving and new drug candidates, may not prove safe and groan or important, the possibility that our existing and new drug candidates may not receive commendation from the FDA, and other regulatory agencies in a timely bearing or in any way, the possibility that our existing and new drug candidates, if certified, may not be more effective, safer or more whole modernized than opposing drugs, the possibility that allowance and other aggressive pressure may product the marketing and mart of our generic drugs not commercially reasonable, the possibility that our pains to acquire or in-license and develop extramural drug candidates may spring improper, our lack of revenues, our limited go through in establish strategic alliances, our limited marketing experience, our limited experience with the generic drug industry, our drive on ultimate of third party for clinical trials, production, scattering and quality direct and other risks that are label in further tiny spike in the Company's reports filed with the Securities and Exchange Commission. We people out not arrangement to update any such forward-looking statements and expressly disclaim any monies to update the information contained here press release apart from as chief with imperative.

Spectrum Pharmaceuticals, Inc.

Read more about best tabs price